C9581 evaluated edrecolomab versus observation in patients with stage II CC and reported no survival benefit. Under an initial case-cohort sampling design, a randomly selected subcohort (RS) comprised ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results